HopeStage
Back to all studies
Not Yet RecruitingNCT07148206

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

Medication studyAges 18+United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: from 18 years.

Listed locations
The BronxSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: October 2026
Recruitment status
Not Yet Recruiting
Enrollment listed in the registry
40
Sponsor
Montefiore Medical Center
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT07148206
Official title
Show the full official title

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

Recruitment & locations

Not yet recruiting

The Bronx

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Montefiore Medical Center, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Dronabinol Capsules and Epidiolex 100 mg/mL Oral Solution.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as not yet recruiting.

Want to explore more studies?

Explore studies